Indications for: CRINONE

Progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency.

Adult Dosage:

Supplementation: 1 applicatorful intravaginally once daily. Replacement: 1 applicatorful intravaginally twice daily. If pregnancy occurs, may continue treatment until placental autonomy is achieved (10–12 weeks).

Children Dosage:

Not applicable.

CRINONE Contraindications:

Undiagnosed vaginal bleeding. Breast or genital carcinoma. Liver dysfunction or disease. Missed abortion. Thrombophlebitis or thromboembolic disorders.

CRINONE Warnings/Precautions:

Conditions aggravated by fluid retention. Depression. Include Pap smear with pretreatment exam. Discontinue if signs of thrombotic disorders (eg, thrombophlebitis, cerebrovascular disorders, pulmonary embolism, retinal thrombosis) occur. Pregnancy: see literature. Nursing mothers.

CRINONE Interactions:

Allow at least 6 hours between administration of this and other vaginally-administered products.

Adverse Reactions:

Mastodynia, constipation, somnolence, GI upset, headache, abdominal/perineal pain, nervousness, cramps, nocturia, depression, decreased libido, arthralgia, bloating, pain, vaginal candidiasis/discharge, dizziness, dyspareunia, pruritus genital, allergy, fatigue, urinary tract infection, others.


Hepatic. ~96–99% serum protein bound.

Drug Elimination:

Renal, fecal. Half-life: 5–20 minutes.

How Supplied:

Prefilled applicators—18